Skip to main content
. Author manuscript; available in PMC: 2019 May 25.
Published in final edited form as: Pharm Nanotechnol. 2018;6(4):232–244. doi: 10.2174/2211738506666180918122337

Fig. (3).

Fig. (3).

Antitumor efficacy using liposomal NPs to deliver STING agonists. a) BALB/c mice were subcutaneously injected with liposomal cyclic di-GMP (NP-cdGMP) or soluble cdGMP. The accumulation of fluorescently tagged cDGMP in lymph nodes was traced by fluorescence spectroscopy. C57BL/6 mice were immunized with OVA, OVA+cdGMP, or OVA+NP-cdGMP on days 0 and 14. b) PBMCs were restimulated ex vivo and analyzed by flow cytometry to determine the population of IFN-γ and TNF-α producing CD8+ T-cells. C57BL/6 mice were subcutaneously injected with EG.7-OVA cells and vaccinated with OVA, OVA+cdGMP, or OVA+NP-cdGMP on days 6, 13, and 20. c) Tumor area and d) survival were measured over time [87].